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DREAM Is a Critical Transcriptional Repressor
for Pain Modulation
volved in modulating pain. dream/ mice displayed
markedly reduced responses in models of acute ther-
mal, mechanical, and visceral pain. dream/mice also
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Control and treatment of chronic pain remain major DREAM (downstream regulatory element antagonistic
clinical challenges. Progress may be facilitated by a modulator) was identified in in vitro studies as a putative
greater understanding of the mechanisms underlying transcriptional repressor for the prodynorphin gene
pain processing. Here we show that the calcium-sens- (Carrion et al., 1999), which contains a consensus DNA
ing protein DREAM is a transcriptional repressor in- sequence, or downstream regulatory element (DRE), re-
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conditions (Carrion et al., 1998). DREAM possesses di- (Figures 1C and 1D). dream/ mice were born at the
expected Mendelian frequency, were fertile, appearedrect calcium binding ability (by virtue of four EF-hand
motifs) and calcium binding to DREAM blocks its ability healthy, and displayed longevity that was indistinguish-
able from wild-type littermates.to associate with DNA (Carrion et al., 1999). With homol-
ogy to members of the neuronal calcium sensor (NCS)
superfamily, DREAM is the first transcription factor Lack of DREAM Has No Detectable Effect on Heart
known to be directly regulated via calcium binding. In Function or Presenilin Processing
addition to prodynorphin, DREAM was believed to regu- DREAM mRNA expression is detectable in the brain and
late the expression of other DRE-containing genes, for nonneuronal tissues including the heart, testis, kidney,
example, c-fos (Carrion et al., 1999), and may represent bone marrow, and thymus (unpublished data; Buxbaum
a new paradigm in calcium-dependent gene expression. et al., 1998; Carrion et al., 1999; Spreafico et al., 2001).
Despite evidence suggesting that DREAM is a tran- At 3 and 7 months of age, dream/ mice were indistin-
scription factor, the physiological function of dream has guishable from wild-type littermates with regards to
remained unclear. The discovery of two nearly identical structure and morphology of all tissues, as well as hema-
EF-hand proteins, calsenilin (Buxbaum et al., 1998) and tological and serological parameters. Development, ho-
KChIP3 (Kv channel-interacting protein 3) (An et al., meostasis, and function of hematopoietic cells were
2000), encoded by the same genomic locus as DREAM, comparable between the two genotypes (data not
suggested different biological functions for a single shown).
gene. As a calcium-regulated binding partner of preseni- DREAM (KChIP3) has been implicated as a potential
lin, calsenilin/DREAM has been suggested to be in- positive modulator of Kv4 potassium channels (An et
volved in the proteolytic processing of presenilins and al., 2000). Loss of Kv4.2-dependent cardiac IAF currents
the formation of amyloid plaques in Alzheimer’s disease in transgenic mice overexpressing dominant-negative
(Buxbaum et al., 1998; Choi et al., 2001; Jo et al., 2001). Kv4.2 results in enlargement of the heart by 10–16 weeks
KChIP3/DREAM was cloned as a binding partner and of age, leading to congestive heart failure and premature
direct modulator for A type (Kv4) potassium channels death (Wickenden et al., 1999). We hypothesized that
(An et al., 2000), which have been implicated in the lack of DREAM might impair Kv4 activity in the heart to
pathogenesis of heart failure (Wickenden et al., 1999). produce a phenotype similar to that observed in Kv4.2
Given the potential involvement and identification of transgenic mice. However, we found that at 4 months
DREAM/calsenilin/KChIP3 in three distinct biological of age, dream/ mice were indistinguishable from wild-
systems in in vitro studies, the physiological function of type littermates with regards to the heart-to-body mass
DREAM awaited further clarification. ratios (data not shown). While 3- and 14-week-old Kv4.2
To elucidate the role of DREAM in vivo, we generated transgenic mice displayed altered heart functions by
dream/ mice. Here we show that DREAM is essential echocardiographic analysis (Wickenden et al., 1999), our
for transcriptional repression of the prodynorphin gene studies revealed no significant difference in these pa-
in spinal cord neurons. Lack of DREAM in mutant mice rameters between wild-type and dream/ littermates
results in marked attenuation in pain behaviors regard- at a similar age. Heart morphology, function, and con-
less of the modality of the noxious stimuli (thermal, me- tractility were likewise indistinguishable between the
chanical, or chemical) or the tissue type (cutaneous or two genotypes of more advanced age (7 months; data
visceral) affected. In addition to reduced acute pain, not shown).
loss of DREAM similarly results in attenuation of both DREAM (calsenilin) has been suggested to regulate
inflammatory and neuropathic pain behavior, the latter the proteolytic processing of presenilin 1 (PS1) and pre-
incurred by peripheral nerve injury. Activation of the senilin 2 (PS2) (Buxbaum et al., 1998; Choi et al., 2001)
dynorphin-selective -opiate receptor was found to be and to potentiate presenilin-induced apoptosis in vitro
causal to the reduced pain responses in dream/ mice. (Jo et al., 2001). Western blot analyses of PS1 and PS2
These findings identify DREAM as a critical transcrip- in membrane-enriched brain extracts revealed no de-
tional repressor for pain modulation. tectable difference in the total expression levels be-
tween wild-type and dream/ mice, nor in the occur-
rence or sizes of differentially processed C-terminal PS1Results
and PS2 fragments (data not shown). Furthermore, we
did not detect structural or neuroanatomical abnormali-Generation of dream/ Mutant Mice
ties, which would otherwise suggest defects in cell sur-The dream gene was disrupted in murine embryonic
vival, in the brains of dream/ mice at 7 months ofstem (ES) cells using a targeting vector in which nucleo-
age. Taken together, we find no evidence to suggest antides encoding amino acids 58–143, corresponding to
essential involvement of DREAM in presenilin pro-EF hands I and II and the proximal 5 region, were de-
cessing or Kv4-dependent heart functions.leted (Figure 1A). The targeting construct was electro-
porated into ES cells. Two G418-resistant cell lines het-
erozygous for the mutation at the dream locus were General Behavioral Assessment of dream/ Mice
We subsequently evaluated the behavior of these mu-used to generate chimeric mice, which were crossed to
C57BL/6 to obtain heterozygous dream/ mice. The tant mice (see Supplemental Table S1 at http://www.cell.
com/cgi/content/full/108/1/31/DC1). dream/ animalsintercross of dream/ mice produced homozygous
dream/ mice, as confirmed by Southern blot analysis were indistinguishable from wild-type littermates in lo-
comotor responses under nonstressful (locomotor ac-(Figure 1B). The null mutation of dream was verified by
the absence of dream mRNA transcripts and protein tivity box) and stressful (open-field test) conditions. The
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Figure 1. Targeted Disruption of the dream Locus by Homologous Recombination
(A) Gene targeting strategy. Top: wild-type dream locus showing exons 3–9 (III–IX; filled boxes). Middle: targeting vector in which exons 3–5
were replaced with the neomycin (neo) resistance marker and the thymidine kinase (TK) marker was inserted at the 3 end. Bottom: mutated
dream locus. “N” indicates NheI. The 5 flanking probe is shown.
(B) Southern blot analysis of NheI-digested genomic DNA from dream/, dream/, and dream/ mice.
(C) Northern blot analysis of dream mRNA expression in the brains of dream/, dream/, and dream/ mice.
(D) Western blot analysis of DREAM protein expression in the brains of dream/, dream/, and dream/ mice.
degree of anxiety (defecation) was comparable between nal writhing) independent of inflammation, and injection
of acetic acid, which induces pain secondary to an in-the two genotypes, as was the performance in the light/
dark activity box. Motor coordination and balance were flammatory reaction. dream/ mice demonstrated a
striking reduction in the number of abdominal writhesunimpaired in dream/ mice (see also Figure 2A).
dream/ mice displayed more hindlimb placement er- relative to wild-type in both tests of visceral pain (Figures
2E and 2F).rors relative to wild-type mice in the grid-walking task,
indicating a mild impairment of gross motor skills. How- As noted above, dream/ mice performed as well as
wild-type animals in tests of motor coordination andever, reaching tasks showed that fine motor control of
the forelimbs was intact. In the place-learning version skill. Furthermore, responses to nonnoxious tactile stim-
uli, as well as orienting responses to auditory cues, wereof the Morris water maze, acquisition of the spatial task
was not different between dream/ and wild-type mice indistinguishable between the two genotypes (data not
shown; see Supplemental Data, Experimental Proce-(Figure 2B). These data indicate that lack of DREAM
does not result in substantial abnormalities in locomotor dures). Thus, the observed reduction in pain behavior
evoked by noxious cutaneous and visceral stimuli ap-activities, motor skills and coordination, anxiety, or spa-
tial learning and memory. pears to be due to an alteration in nociceptive pro-
cessing, rather than a defect in motor or general sensory
functions in dream/ mice.Reduced Thermal and Mechanical Cutaneous
and Chemical Visceral Pain in dream/ Mice
During our behavioral screening analysis, we observed Lack of DREAM Attenuates Chemical-Induced
and Inflammatory Painthat dream/ mice displayed significantly longer re-
sponse latency compared with wild-type littermates in The effect of DREAM ablation on chemical pain behavior
was assessed in the formalin test. Intradermal injectionthe tail-flick test of cutaneous thermal nociception (Fig-
ure 2C). In a test of cutaneous mechanical pain, the of formalin into the hindpaw produced biphasic paw-
licking behavior in both wild-type and dream/ mice;threshold required to elicit hindpaw withdrawal in re-
sponse to mechanical pressure was greater in dream/ however, the magnitude of the response in both phases
was significantly reduced in dream/ animals (Fig-mice than in wild-type littermates (Figure 2D).
To determine whether the reduced pain responses in ure 3A).
Pain behavior associated with inflammation was sub-dream/ mice were generalized to noxious stimulation
of other tissues, we assessed acute visceral pain behav- sequently determined in a model of neurogenic inflam-
mation induced by capsaicin injection into the hindpaw,ior evoked by intraperitoneal injection of MgSO4, which
produces an immediate visceral pain response (abdomi- which elicits an acute licking response as well as me-
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played decreased mechanical hypersensitivity relative
to wild-type at 4 and 24 hr. The degree of carrageenan-
induced inflammation was indistinguishable between
the two genotypes at all time points (Figure 3F). Hence,
in three models involving inflammation, dream/ mice
demonstrated reduced pain behavior. Thus, our data
show that DREAM has an essential role in the modula-
tion of chemical and inflammatory pain, without being
required for the inflammatory response per se.
Attenuated Neuropathic Pain Behavior
of dream/ Mice
We assessed the potential involvement of DREAM in a
model of neuropathic pain (chronic constriction of the
sciatic nerve) that mimics peripheral nerve injury in hu-
mans (Mosconi and Kruger, 1996; Pitcher et al., 1999).
The change in paw withdrawal threshold following cuff
implantation around the sciatic nerve was determined
for 18 days post-cuff implantation (p.c.i.). Wild-type ani-
mals displayed a pronounced reduction in paw with-
drawal threshold at all time points subsequent to nerve
constriction (Figure 4). Moreover, spontaneous pain be-
havior (characterized by rapid shaking, guarding, and
lifting of the hindpaw) was apparent in 10 out of 21
wild-type animals beginning at day 4 p.c.i. In contrast,
dream/ mice were significantly less hypersensitive to
innocuous mechanical stimuli compared with wild-typeFigure 2. Reduced Pain to Noxious Cutaneous and Visceral Stimuli
in dream/ Mice animals at all time points following cuff implantation
(A) Rotarod test. Duration (s) that mice remain on the rotating rod (Figure 4). Spontaneous pain behavior was not observed
at increasing speeds. in any of the nerve-cuffed dream/ animals throughout
(B) Place learning in the Morris water maze. Escape latency indicates the 18 day study period. Sham-operated animals did not
the time required to reach the hidden platform at different trials. (A
show any significant changes in mechanical thresholdsand B) Two-factor ANOVA.
(data not shown). Thus, following peripheral nerve injury,(C) Tail-flick test. Values represent the latency (s) to tail flick from
dream/ mice displayed marked resistance to devel-the heat source. Two-tailed Student’s t test. Triple asterisk indicates
p  0.001 versus wild-type. oping tactile allodynia (hypersensitivity to innocuous
(D) Mechanical pain test. Values indicate the threshold (g/mm2) to mechanical stimuli) and spontaneous pain behavior.
elicit a paw withdrawal reflex in response to noxious mechanical
stimuli. Single asterisk indicates p  0.05 versus wild-type.
Direct Binding of Murine DREAM to Prodynorphin(E and F) Visceral pain in response to (E) MgSO4 (120 mg/kg) or
and c-fos DRE Sequences(F) acetic acid (0.6%). Values represent the number of abdominal
stretches (writhes). n  8–12 for each group. All data are presented Previous studies implicated DREAM as a putative tran-
as mean 	 S.E.M. (D–F) Mann-Whitney test. (E) Triple asterisk indi- scriptional repressor for the prodynorphin and c-fos
cates p  0.001 versus wild-type. (F) Double asterisk indicates p  genes (Carrion et al., 1999). Sequence alignment
0.01 versus wild-type. showed that the prodynorphin (Dyn), c-fos and proen-
kephalin (Penk) genes harbor intragenic sequences re-
sembling the proposed consensus DRE (Carrion et al.,chanical hypersensitivity (hyperalgesia). The licking re-
sponse following capsaicin injection was significantly 1998; Figure 5A). Since dream/ mice displayed mark-
edly reduced pain responses, we tested whether murineattenuated in dream/ mice compared with wild-type
mice (Figure 3B). Whereas sensitivity to innocuous me- DREAM could bind to DRE elements of the prodynorphin
gene.chanical stimulation was indistinguishable between
wild-type and dream/mice prior to capsaicin injection, In electrophoretic mobility shift assays (EMSA), bind-
ing of purified recombinant murine DREAM to wild-typecapsaicin elicited a profound reduction in paw with-
drawal threshold in wild-type animals (Figure 3C). In prodynorphin DRE occurred in a dose-dependent fash-
ion and was abrogated by the addition of calcium (Figurecontrast, capsaicin-induced mechanical hyperalgesia
was attenuated in dream/ mice (Figure 3C). The de- 5B). Binding of DREAM to wild-type prodynorphin DRE
was competed specifically with unlabeled wild-typegree of capsaicin-induced inflammation, as indicated
by swelling of the injected paw, was not significantly DRE oligonucleotide (Figure 5C, compare lanes 1 and 2)
but not with two different mutant DRE oligonucleotidesdifferent between the two genotypes (Figure 3D).
Another inflammatory pain model, carrageenan injec- harboring point mutations in the GTCA consensus bind-
ing site (Figure 5C, lanes 3 and 4) or with an irrelevanttion into the hindpaw, evokes a mechanical hyperalgesic
response. Following carrageenan injection, paw with- cAP-1 oligonucleotide (Figure 5C, lane 5). Similarly,
c-fos DRE can bind to DREAM (Figure 5D, lane 1); bind-drawal threshold in wild-type animals was profoundly
reduced at 4 and 24 hr, and gradually recovered to ing was abrogated with unlabeled wild-type c-fos DRE
(Figure 5D, lane 2) but not cAP-1 oligonucleotides (Fig-baseline level by 96 hr (Figure 3E). dream/ mice dis-
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Figure 3. Reduced Chemical and Inflamma-
tory Pain Behavior in dream/ Mice
(A) Formalin test. Values represent time (s)
spent in paw licking in each 5 min interval
following 2% formalin injection. Neuman-
Keuls test. Single asterisk indicates p 0.05;
double asterisk indicates p  0.01 versus
wild-type.
(B–D) Capsaicin-induced pain behavior.
(B) Time (s) spent in paw licking within the first
5 min following capsaicin (0.3 g) injection.
Two-tailed Student’s t test. Single asterisk
indicates p  0.05 versus wild-type.
(C) Mechanical sensitivity before (pre-CAP)
and 20 min (post-CAP) following capsaicin
injection. Values represent the paw with-
drawal threshold as a percentage of the base-
line (pre-CAP) wild-type response. Tukey-
Kramer test. Single asterisk indicates p 
0.05 versus wild-type. Single hatch mark indi-
cates p  0.05; double hatch mark indicates
p  0.01 versus preinjection values.
(D) Capsaicin-induced paw swelling. Values represent the paw thickness 30 min after capsaicin injection as a percentage of preinjection paw
thickness. Two-tailed Student’s t test.
(E and F) Carrageenan-induced inflammatory pain.
(E) Mechanical sensitivity 0–96 hr following 
-carrageenan (2%) injection. Values represent the paw withdrawal threshold as a percentage of
the baseline (0 hr) wild-type response. Neuman-Keuls test. Single asterisk indicates p  0.05; double asterisk indicates p  0.01 versus wild-
type.
(F) Carrageenan-induced paw swelling. Values are represented as described in (E). n  8–11 for each group. All data are presented as mean 	
S.E.M. Two-factor ANOVA.
ure 5D, lane 3). These data show that murine DREAM of the spinal cord as well as the hippocampus, we could
not detect DREAM protein in dorsal root ganglia (DRG)can associate directly and specifically with DRE ele-
(Figure 5E). In keeping with protein expression data,ments and that binding of calcium to DREAM abolishes
dream mRNA was robustly expressed in the ventral andthe DREAM-DRE interaction.
dorsal horns of the lumbar spinal cord of wild-type mice
(Figure 6A). These results suggest that the effect ofEnhanced Basal Expression of Prodynorphin
DREAM ablation on pain behavior is not due to a cell-in dream/ Spinal Cord
autonomous defect in peripheral sensory neurons.Nociceptive information is transmitted through a “pain
Rather, it is likely that DREAM modulates pain pro-pathway,” which begins at the periphery with the stimu-
cessing at the level of the spinal cord and/or brain.lus-dependent activation of sensory nerves, through the
Given the proposed function of DREAM as a transcrip-spinal cord as a result of neurotransmitter release, and
tional repressor, we analyzed the abundance of various
eventually to the brainstem and forebrain, where the
gene transcripts in the lumbar spinal cords of wild-type
information is integrated to produce a “pain experience”
and dream/ mice by in situ hybridization. In wild-type
(Woolf and Salter, 2000). Hence, DREAM may be func- mice, the basal expression of prodynorphin mRNA was
tioning at multiple levels to modulate pain. While DREAM detected mainly in scattered neurons of the superficial
protein was expressed in the ventral and dorsal horns dorsal horn (Figure 6C). In contrast, dream/ mice
showed markedly increased basal prodynorphin ex-
pression throughout the lumbar spinal cord (Figure 6D).
However, we detected no difference in the basal level
of proenkephalin (Figures 6F and 6G) or c-fos (Figures
6L and 6M) mRNA between dream/ and wild-type lit-
termate mice. Expression of proopiomelanocortin was
comparable in the spinal cord of dream/ and wild-
type mice (Figures 6I and 6J). In contrast, the brains
and hippocampi of wild-type and dream/ mice did not
differ in their abundance of prodynorphin (Figure 7A) or
c-fos (data not shown) mRNA by Northern blot analyses.
Together, our data support an essential role of DREAM
in repressing basal expression of the prodynorphin gene
in the spinal cord.
Figure 4. Reduced Neuropathic Pain Behavior in dream/ Mice
DREAM Represses Basal Expression of ProdynorphinPaw withdrawal thresholds (g/mm2) following cuff implantation
in Primary Spinal Cord Culturesaround the sciatic nerve. n  18–21 for each group. Data are pre-
To confirm the elevated basal expression of prodynor-sented as mean 	 S.E.M. Single asterisk indicates p  0.05; double
asterisk indicates p  0.01 versus wild-type (Neuman-Keuls test). phin in the spinal cord, we carried out RT-PCR analysis
Cell
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level beyond basal expression. This is consistent with
the notions that (1) spinal cord neurons contain constitu-
tively expressed transcription factor(s) which can trans-
activate the prodynorphin gene in the absence of
DREAM protein and (2) DREAM critically determines
basal expression of prodynorphin in the spinal cord.
Enhancement of Spinal Dynorphin But Lack
of -Opiate Receptor Downregulation
in dream/ Mice
To assess whether the enhanced basal level of spinal
prodynorphin mRNA is accompanied by a concurrent
increase in dynorphin peptide content, the amount of
dynorphin A(1–17) and dynorphin A(1–8) in the spinal cord
was determined by enzyme immunoassay. The level of
dynorphin A(1–17) but not dynorphin A(1–8) was greater in
the spinal cords of dream/ mice than those of wild-
type littermates (Figure 7E). We conclude that elevated
prodynorphin mRNA levels are reflected in increased
synthesis of dynorphin in dream/ spinal cord. In addi-
tion, protein expression of -opiate receptor (KOR1),
NMDA receptor (NMDAR1), and PSD-95 was not per-
turbed in dream/ spinal cord (Figure 7F).
Decreased Pain Behavior of dream/ Mice
Is Mediated via -Opiate Receptors
Endogenous opioids and their cognate receptors have
been strongly implicated in pain modulation (Dickenson,
1991; Suzuki et al., 1999). Dynorphins are believed toFigure 5. Direct Binding of Murine DREAM to DRE Sequences
exert their antinociceptive action predominantly through(A) Proposed DRE consensus sequence and alignment of human
 -opiate receptors (Goldstein and Naidu, 1989). There-and mouse prodynorphin (Dyn), c-fos, and proenkephalin (Penk)
DRE. fore, by using a pharmacological approach, we investi-
(B) Murine DREAM (mDREAM) binding to prodynorphin DRE using gated the functional relevance of enhanced dynorphin
EMSA. Binding of mDREAM (lane 1, 0 M; lane 2, 10 M; lane 3, expression in dream/ mice on their pain behavior phe-
20 M; lane 4, 30 M; lane 5, 40 M; and lane 6, 50 M) with Cy5-
notype.labeled DynDRE (5 nM) with () or without () 10 mM Ca2.
Neither the pan-opiate receptor antagonist naloxone(C) Competition of mDREAM (40 M) binding to DynDRE (5 nM)
nor the -selective antagonist nor-BNI altered the tail-using wild-type DynDRE (lane 2; 75 nM), DREmut5 (lanes 3; 75 nM),
DREmut4 (lane 4; 75 nM), or control cAP-1 (lane 5; 75 nM). (Lane 1) flick latency or the threshold to paw withdrawal in re-
Binding of mDREAM (40 M) to wild-type DynDRE (5 nM). sponse to noxious mechanical stimuli in wild-type ani-
(D) mDREAM binding to c-fosDRE using EMSA. (Lane 1) mDREAM mals (Figures 8A and 8B). In contrast, administering
(40 M) was incubated with Cy5-labeled c-fosDRE (5 nM) with ()
either naloxone or nor-BNI produced a significant reduc-or without () 10 mM Ca2. Competition with 50 nM unlabeled
tion in each of the acute pain measures in dream/c-fosDRE (lane 2) or cAP-1 (lane 3).
mice, resulting in nociceptive responses that were indis-(E) Western blot analyses of DREAM expression in the dorsal and
ventral horns of the spinal cord, hippocampus, and dorsal root gan- tinguishable from those of wild-type mice (Figures 8A
glia (DRG). and 8B). Antagonism of peripheral opiate receptors us-
ing naloxone methiodide had no significant effect on the
tail-flick latencies of either genotype: tail-flick latency (s)
following vehicle versus naloxone methiodide injectionof prodynorphin mRNA in primary spinal cord cultures
established from wild-type and dream/ embryos. The in wild-type mice, 4.3 	 0.3 versus 4.3 	 0.3, p  0.05;
in dream/ mice, 6.8 	 0.4 versus 6.5 	 0.5, p  0.05.basal level of prodynorphin mRNA was markedly greater
in dream/ spinal cord culture compared with that in In the carrageenan model, nor-BNI did not signifi-
cantly alter the paw withdrawal threshold of wild-typewild-type (Figure 7B), whereas the basal expression of
c-fos mRNA was similar between dream/ and wild- animals (Figure 8C). However, nor-BNI restored the paw
withdrawal threshold of dream/ mice to the level ob-type cultures (Figure 7C). In addition, wild-type and
dream/ cultures were stimulated with agonists pre- served in wild-type littermates (Figure 8C). Naloxone
methiodide did not have a significant effect on the me-viously shown to induce prodynorphin transactivation
(Lucas et al., 1993; Messersmith et al., 1994). In wild-type chanical threshold in either genotype: paw withdrawal
threshold (represented as percent wild-type [wt] base-cultures, serotonin, 8-OH-DPAT (serotonin 1A receptor
agonist), and forskolin (adenylate cyclase agonist) each line control) in the absence versus presence of naloxone
methiodide in wild-type mice, 31.3 	 8.4 versus 34.7 	were able to induce prodynorphin mRNA expression
(Figure 7D). Under these culture conditions, we did not 4.6, p 0.05; in dream/ mice, 75.2	 3.1 versus 61.3	
8.2, p 0.05. In the formalin test, nor-BNI eliminated theobserve further enhancement of prodynorphin mRNA
DREAM and Transcriptional Modulation of Pain
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Figure 6. DREAM Represses Basal Prody-
norphin Expression in the Spinal Cord
In situ hybridization analyses of the expres-
sion patterns of dream, prodynorphin, proen-
kephalin, proopiomelanocortin, and c-fos
mRNA in the lumbar spinal cord. mRNA ex-
pression of (A and B) dream, (C and D) prody-
norphin (pdyn), (F and G) proenkephalin
(penk), (I and J) proopiomelanocortin (pomc),
and (L and M) c-fos in the lumbar spinal cord
of (A, C, F, I, and L) wild-type and (B, D, G,
J, and M) dream/ mice determined using
gene-specific antisense cRNA probes. Sense
controls for (E) pdyn, (H) penk, (K) pomc, and
(N) c-fos in wild-type mice. Insets show the
same lumbar spinal cord section under lower
magnification. The scale bar equals 200 m.
difference between genotypes in the licking response in receptor antagonist MK-801 on pain responses in the
tail-flick test and neuropathic model. We used MK-801both the acute and tonic phase (data not shown).
In our model of neuropathic pain, nor-BNI had no at doses reported to block behavioral effects mediated
by NMDA receptors (see also Figure 8E and Jevtovic-significant effect on mechanical hypersensitivity of wild-
type animals at day 18 p.c.i. (Figure 8D). In contrast, Todorovic et al., 1998). Higher doses of MK-801 were not
tested because we observed extrasensory behavioralthe paw withdrawal threshold of dream/ mice was
significantly reduced by nor-BNI, although it did not effects, including hyperactivity, head weaving, body roll-
ing, and circling, in pilot studies using this mouse strain.produce a complete reversal to wild-type hypersensitiv-
ity in these animals (Figure 8D). Likewise, naloxone ad- NMDA receptors are not implicated in mediating acute
thermal nociception (Lutfy et al., 1997), making this aministered at day 18 p.c.i. reduced the paw withdrawal
threshold of dream/ animals without producing an suitable model in which to examine NMDA receptor acti-
vation (tonic or stimulus-evoked) in dream/ mice. MK-effect in wild-type mice: paw withdrawal threshold
(g/mm2) at day 18 in the absence versus presence of 801 had no effect on the tail-flick latency of wild-type
animals (Figure 8E). The tail-flick latency of dream/naloxone in wild-type mice, 8.0 	 1.4 versus 7.9 	 1.4,
p  0.05; in dream/ mice, 38.0 	 7.1 versus 23.5 	 mice was likewise unaltered by MK-801 (Figure 8E).
The contribution of NMDA receptor activation in neu-3.3, p  0.05. In contrast, naloxone methiodide did not
significantly alter the paw withdrawal thresholds in either ropathic pain is well established (Woolf and Mannion,
1999). In wild-type animals, MK-801 administered at daygenotype: paw withdrawal threshold (g/mm2) in the ab-
sence versus presence of naloxone methiodide in wild- 18 p.c.i. produced a dose-dependent increase in paw
withdrawal thresholds (Figure 8F). In contrast, at neithertype mice, 11.6 	 2.5 versus 12.6 	 2.4, p  0.05; in
dream/ mice, 38.0 	 5.8 versus 31.8 	 5.4, p  0.05. of the doses tested did MK-801 alter the already ele-
vated paw withdrawal thresholds of dream/ mice.Collectively, the data suggest that there is enhanced
activation (either tonic or stimulus-evoked) of -opiate Therefore, we conclude that NMDA receptor activity is
not essential for the reduced mechanical hypersensitiv-receptors in dream/ mice and that this -opiate recep-
tor activity is required to mediate the reduced pain be- ity observed in neuropathic dream/ mice.
haviors in these animals.
Discussion
NMDA Receptor Blockade Does Not Alter Pain
Behaviors in dream/ Mice To elucidate the essential role(s) of DREAM in vivo, we
generated dream-deficient mice and found these ani-Although the -opiate receptor-mediated antinocicep-
tive effects of dynorphins are well established, there are mals to exhibit markedly attenuated pain responses in
a battery of pain behavior tests. The reduction in painreports indicating that dynorphin may exert pronocicep-
tive effects through an interaction with NMDA receptors responses was observed in the absence of any substan-
tial deficit to nonnoxious sensory and motor function,(Laughlin et al., 1997; Vanderah et al., 1996). To assess
the role of NMDA receptors in the pain behavior of learning or memory, and immune or cardiac functions.
The reduced pain behavior of dream/ mice was corre-dream/ mice, we investigated the effect of the NMDA
Cell
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Figure 7. Enhancement of Spinal Prodynorphin mRNA and Peptide Content But Lack of -opiate Receptor Downregulation in dream/ Mice
(A) Northern blot analysis of dream mRNA expression in dream/, dream/, and dream/ mouse brain and hippocampus.
(B and C) Basal expression of (B) prodynorphin and (C) c-fos mRNA in cultured wild-type and dream/ spinal cord neurons as assessed by
semiquantitative RT-PCR. gapdh mRNA served as the control (data not shown). Graphs represent the relative abundance of prodynorphin-
or c-fos-specific PCR products between the two genotypes.
(D) Induction of prodynorphin mRNA expression in primary spinal cord cultures. RT-PCR analysis of prodynorphin mRNA content in cultures
without stimulation or stimulated with 8-OH-DPAT (100 nM), serotonin (100 nM), or forskolin (25 M).
(E) ELISA quantitation of spinal dynorphin A(1–17) and dynorphin A(1–8) levels in wild-type (n  5) and dream/ (n  5) mice 3 hr following
intrathecal administration of the peptidase inhibitors, p-hydroxymercuribenzoate (8 nmol) and phosphoramidon (4 nmol). Triple asterisk
indicates p  0.001 versus wild-type (two-tailed Student’s t test).
(F) Western blot analyses of the -opiate receptor (KOR1), NMDAR1 receptor subunit (NMDAR1), and postsynaptic density-95 (PSD-95) in
membrane fractions of the spinal cord, brainstem, and brain of wild-type and dream/ mice.
lated with enhanced basal expression of spinal prody- channel modulators in the absence of DREAM. As
DREAM is found in both nuclear and membrane fractionsnorphin mRNA and dynorphin peptides. In vitro studies
confirmed the specific DNA binding ability of murine of the mouse brain (data not shown), the physiological
function(s) besides its role in transcriptional repressionDREAM for the prodynorphin DRE sequence. The func-
tional relevance of dynorphin upregulation was apparent remains to be defined. Interestingly, the EF-hand protein
secretagogin has been revealed to have repressor activ-from pharmacological studies, where -opiate receptor
blockade by nor-BNI reversed the pain response of ity on the substance P promoter (Wagner et al., 2000),
suggesting the possible existence of a family of calciumdream/ mice. Together, our data are consistent with
an essential role of DREAM both in the transcriptional binding transcription factors.
Our pharmacological studies indicate that the ob-control of the prodynorphin gene and in pain modu-
lation. served attenuation of pain responses in dream/ mice
is mediated by -opiate receptor activity. AdministeringIn addition to the postulated role of DREAM as a tran-
scriptional repressor, DREAM has also been shown to nor-BNI resulted in complete reversal of pain behavior
of dream/ mice to that of wild-type animals in modelsassociate physically with presenilins (Buxbaum et al.,
1998) and Kv4 potassium channels (An et al., 2000), and, of acute, chemical, and inflammatory pain. Our data are
consistent with the notion that -opiate receptors arehence, may modulate their functions. Although our data
do not exclude a physiological involvement of DREAM tonically activated in dream/ mice and/or that there
is enhanced -opiate receptor activation as a conse-in presenilin and/or Kv4 function, presenilin and/or heart
functions dependent upon Kv4 activity do not appear to quence of somatosensory stimulation in dream/ ani-
mals. The lack of -opiate receptor downregulation, atbe compromised in dream/ mice. Notably, the DREAM
homologs KChIP1, KChIP2, and KChIP4, as well as an- the protein level, in dream/ mice provides additional
support that the observed analgesia in dream/animalsother EF-hand protein, frequenin, are able to interact
with Kv4  subunits (An et al., 2000; Nakamura et al., is functionally mediated by these receptors.
In the neuropathic model, neither naloxone nor nor-2001), suggesting compensation by other potassium
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Figure 8. Involvement of -Opiate Receptors
But Not NMDA Receptors in the Observed
Analgesia in dream/ Mice
(A and B) Effects of naloxone (1 mg/kg, i.p.)
and nor-BNI (2 mg/kg, s.c.) in (A) the tail-flick
test and (B) the mechanical pain test. Two-
factor ANOVA and post-hoc tests. Triple as-
terisk indicates p  0.001 versus wild-type
group receiving the same treatment. Single
hatch mark indicates p  0.05 versus vehicle
(untreated) group of the same genotype.
(C) The effect of nor-BNI on the paw with-
drawal threshold in the carrageenan model.
Animals received nor-BNI (2 mg/kg, s.c.) 1 hr
following 2% carrageenan injection. Values
represent the paw withdrawal threshold at 24
hr postcarrageenan injection as a percentage
of the baseline (0 hr) wild-type response.
Two-factor ANOVA and post-hoc tests. Dou-
ble asterisk indicates p  0.01 versus wild-
type group receiving the same treatment.
Single hatch mark indicates p  0.05 versus
vehicle (untreated) group of the same ge-
notype.
(D) The effect of nor-BNI (2 mg/kg, s.c.) on the paw withdrawal threshold (g/mm2) at day 18 p.c.i. in the neuropathic pain model. Two-factor
ANOVA and post-hoc tests. Single hatch mark indicates p  0.05 versus vehicle (untreated) group of the same genotype.
(E) The effect of MK-801 (0.05 mg/kg, s.c.) in the tail-flick test. Two-factor ANOVA and post-hoc tests.
(F) The effect of MK-801 (0.01 and 0.05 mg/kg, s.c.) on the paw withdrawal threshold (g/mm2) at day 18 p.c.i. in the neuropathic pain model.
n  6–10 for each group. All data are presented as mean 	 S.E.M. Two-factor ANOVA and post-hoc tests. Double hatch marks indicate p 
0.01 versus vehicle (untreated) group of the same genotype.
BNI completely restored the blunted mechanical allo- liams, 1993). In addition, dynorphin-mediated activation
of  receptors suppresses calcium currents and cal-dynia of dream/ mice to that of wild-type. This sug-
gests that the attenuated allodynic behavior of dream/ cium-dependent secretion (Rusin et al., 1997; Wiley et
al., 1997). Furthermore, dynorphin has been shown toanimals is not fully dependent on ongoing opiate recep-
tor activation. One possibility is that other mechanisms inhibit substance P release in the spinal cord in a
 receptor-mediated manner (Zachariou and Goldstein,not requiring -opiate receptors are contributing to the
lessened degree of allodynia in dream/ mice. Alterna- 1997). The endogenous dynorphin/-opiate system has
been suggested to elicit antinociception during inflam-tively, tonic activation of -opiate receptors may sup-
press the induction of neuroplastic changes by nerve mation (Schafer et al., 1994) and pregnancy (Dawson-
Basoa and Gintzler, 1996) and to mediate cannabinoid-injury. Hence, the neuroplastic changes may not reach
the full extent observed in wild-type animals and would induced antinociception (Mason et al., 1999). These
studies support an antinociceptive function of dynor-not be expected to be produced by acutely blocking
-opiate receptors. phin by negatively modulating transmission of nocicep-
tive information.Peripheral opiate receptor blockade using naloxone
methiodide did not have a significant effect on acute, Nevertheless, there are reports suggesting that dynor-
phins may exert pronociceptive effects, particularly ininflammatory, or neuropathic pain behavior in dream/
mice. Hence, central -opiate mechanisms are required persistent pain states. Behavioral hyperalgesia as a re-
sult of inflammation (Iadarola et al., 1988) or nerve injuryfor the attenuated pain responses in these animals. Our
evidence of enhanced spinal prodynorphin mRNA and (Kajander et al., 1990) is accompanied by elevations
in spinal dynorphin content, and while the increase indynorphin contents suggests that the dynorphin/-opi-
ate receptor system of the spinal cord is likely mediating dynorphin has been considered causative of the hyper-
algesia, the alternative (that this represents a negativethe analgesic responses in the absence of DREAM.
However, our data do not exclude a possible contribu- feedback) has not been eliminated. Administering exog-
enous dynorphins intrathecally is reported to elicit me-tion of supraspinal opiate mechanisms in the observed
phenotype. chanical allodynia (Laughlin et al., 1997). Recently,
prodynorphin/ mice were generated (Sharifi et al.,Many studies provide support for an antinociceptive
action of dynorphins. Dynorphin-mediated analgesia 2001) and reported to recover more rapidly from the
allodynic state in one model of neuropathic pain (spinalhas been ascribed to its inhibitory action on neurons at
-opiate receptors. Electrophysiological evidence sup- nerve ligation [SNL]) compared with wild-type animals
(Wang et al., 2001). In this study, either MK-801 or antise-ports a -mediated inhibitory effect of dynorphins on
synaptic transmission of nociceptive neurons in the spi- rum to dynorphin A(1–17) alone rescued the enhanced pain
behaviors (i.e., both thermal hyperalgesia and tactilenal dorsal horn (Randic et al., 1995). Dynorphins can
induce hyperpolarization of neurons (Ogura and Kita, allodynia) of wild-type animals to that of prodynor-
phin/ mice. In contrast, another study showed that2000), potentially through a  receptor-coupled en-
hancement of potassium conductance (Grudt and Wil- dynorphin A(1-17) antiserum blocked the thermal hyperal-
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gesia, but not tactile allodynia, after SNL (Malan et al., sites of release. In contrast, when dynorphin’s pronoci-
2000). In conjunction with reports that dynorphin directly ceptive effects are inferred from exogenously adminis-
interacts with NMDA receptors (Tang et al., 1999) and tering dynorphins (for example, by means of intrathecal
may potentiate NMDA currents (Lai et al., 1998) (al- delivery), dynorphin may act in a nonselective manner
though there is also evidence indicating that dynorphin on receptors and cells with which it would not interact
may inhibit NMDA receptors by direct binding [Chen et under physiological conditions. Moreover, a valid com-
al., 1995; Chen and Huang, 1998] or indirectly through parison might not be made between the levels of dynor-
-opiate receptors [Caudle et al., 1994; Ho et al., 1997]), phins achieved in dream/ mice with those following
it has been suggested that dynorphin mediates pronoci- exogenous application.
ceptive effects through NMDA receptors. Given that DREAM can bind to DRE sequences pres-
Using MK-801, we showed that NMDA receptor activ- ent in multiple genes (our results and Carrion et al.,
ity is not required for the increased tail-flick latency 1999), it is intriguing that dream/ mice showed ele-
observed in dream/ mice. In the neuropathic model, vated basal expression of the prodynorphin gene but
while administering MK-801 dose-dependently in- not that of the two other DRE-bearing genes we exam-
creased the paw withdrawal thresholds of wild-type ani- ined, that is, c-fos and proenkephalin. Furthermore, from
mals, MK-801 had no effect on the response of dream/ our study, the increased prodynorphin expression in
mice. Hence, NMDA receptors are not implicated in the dream/ mice appeared to be restricted to the spinal
attenuated neuropathic pain behavior in dream/ mice. cord and not to other tissues examined, including the
One potential explanation for the lack of NMDA receptor brain, thymus, and heart. Hence, ablating DREAM re-
involvement in the allodynia that remains in dream/ sults in altered gene expression in a manner that is both
mice is that there may be insufficient activity of central gene- and tissue-restricted. This points to the impor-
neurons to permit NMDA receptors to become engaged tance of additional transcriptional repressor(s), cofac-
in synaptic transmission. Alternatively, in the absence tors, and/or differential regulation of basal transcription
of DREAM, the downstream consequences of NMDA factors in determining the outcome of lack of DREAM
receptor activity (for example, the signal transduction on gene expression in a particular tissue or cell type in
events downstream of NMDA receptor activation) may vivo.
be suppressed or not expressed.
Our finding that attenuated pain responses in Conclusions
dream/ mice are mediated through -opiate receptors Our results show that lack of DREAM results in attenua-
on a backdrop of elevated spinal dynorphin content is tion of pain responses in models of acute, inflammatory,
juxtaposed with other studies suggesting that dynorphin and neuropathic pain. The reduced pain behavior in
may exert pronociceptive effects, in particular the recent dream/ mice is attributable to -opiate receptor activ-
report that long-term maintenance of neuropathic pain ity. Furthermore, the absence of DREAM results in the
was not observed in prodynorphin/ mice (Wang et enhanced basal expression of prodynorphin in the spinal
al., 2001). How does one reconcile these apparently cord. Biological functions other than pain processing
paradoxical observations? appeared not to be perturbed in dream/ animals. In
First, studies showing that elevation of spinal dynor- summary, our results highlight a new aspect of pain
phin content parallels enhanced pain responses follow- modulation, in which DREAM serves as a “transcrip-
ing tissue or nerve damage are correlative. They do tional switch” for repressing and derepressing endoge-
not resolve the question of whether dynorphin action is nous modulators of pain processing.
responsible for the hyperalgesia, or whether, in fact,
upregulation of dynorphin is a consequence of (and par- Experimental Procedures
ticipates in a feedback inhibitory loop to counteract)
More detailed description of Experimental Procedures is availableincreased nociceptive input following injury.
in the Supplemental Data at http://www.cell.com/cgi/content/full/Second, dynorphins may preferentially act on one or
108/1/31/DC1.another type of receptor, depending upon their concen-
tration. Thus, dynorphin concentration may determine Generation of dream/ Mice
the balance between pro- and antinociceptive effects A targeting vector (667 bp short arm and 7.5 kb long arm) was
(for review, see Laughlin et al., 2001). It has been pro- constructed using the pKO Scrambler NTKV-1907 vector (Stra-
posed that physiological concentrations of dynorphins tagene). A portion of the dream genomic DNA containing dream
cDNA nucleotides 174 to 429 was replaced with the neo cas-are antinociceptive and neuroprotective through opiate
sette. The E14K ES cell line was transfected with this targetingreceptor activation, whereas extremely elevated levels
vector to obtain homologously recombined clones. Two indepen-are pronociceptive and even excitotoxic in an NMDA
dent dream/ ES cell lines were injected into C57BL/6-derived blas-
receptor-dependent fashion (Hauser et al., 1999). The tocysts to generate chimeric mice, which were crossed to C57BL/
lack of -opiate receptor downregulation at the protein 6 mice to produce dream/ mice. Wild-type and dream/ littermate
level in dream/ mice is consistent with the idea that mice generated from heterozygous intercrosses were used for all
-opiate receptor stimulation is neither excessive nor studies. Data reported in this manuscript were consistent between
the two mutant mouse lines. Mice were maintained at the animalto the extent that would produce appreciable internal-
facilities of the Ontario Cancer Institute in accordance with institu-ization and a net decrease in the steady-state level of
tional guidelines.receptors.
Third, in our study, genetic ablation of dream impacts Behavioral Studies
on the endogenous dynorphin system. Endogenous dy- Unless otherwise specified, all behavior studies were conducted
norphins are expected to exert their effects only on a using 4- to 5-month-old mice by observers blinded to the genotypes
of the animals. Assessment of sensorimotor reflex, activity, balancesubpopulation of target receptors and cells near the
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and motor skill, and spatial learning was conducted as previously phoramidon (4 nmol; Sigma), as described previously (Hylden and
Wilcox, 1980; Tan-No et al., 1996). Three hours later, animals weredescribed (Whishaw et al., 1999). Locomotor activities were as-
sessed in a place-conditioning apparatus (Dockstader et al., 2001). sacrificed and spinal cords were removed and stored at70C until
later use. Peptides were extracted as described (Malan et al., 2000).
Levels of dynorphin A(1–17) and dynorphin A(1–8) were determined usingPain Behavior Studies
enzyme immunoassay kits (Peninsula Laboratories).All pain behavior studies were conducted in accordance with the
guidelines in “The Care and Use of Experimental Animals” by the
Western Blotting Analyses of -opiate and NMDACanadian Council on Animal Care and were approved by the Animal
Receptor ExpressionCare Committee of the Princess Margaret Hospital, Toronto, Can-
Membrane fractions were prepared from the brains, brainstems,ada. The tail-flick assay was conducted using a tail-flick analgesia
and spinal cords of wild-type and dream/ mice as describedmeter (Columbus Instruments). The mechanical pain test was per-
(Appleyard et al., 1997). Antibodies to -opioid receptor (KOR-1;formed by applying an ascending series of noxious von Frey hairs
Upstate Biotechnology), NMDA receptor (NMDAR1; PharMingen),to the dorsal surface of each hindpaw until a withdrawal response
and PSD-95 (BD Transduction Laboratories) were used.was observed (Whishaw et al., 1999). In the visceral pain tests, mice
were injected i.p. with MgSO4 (120 mg/kg) or acetic acid (0.6%, 5.0
Acknowledgmentsml/kg) (Cao et al., 1998), and the number of abdominal writhes were
counted within the first 5 min (MgSO4) or 20 min (acetic acid) after
We thank Peter Backx, Rajan Sah, John Roder, John Georgiou,injection. In the formalin test, paraformaldehyde (2%) was injected
Marees Harris-Brandts, Andrew Wakeham, Forrest Haun, Andrewinto the hindpaw, and the time spent paw licking was recorded in
Elia, Takehiko Sasaki, Junko Irie-Sasaki, Kurt Bachmaier, James5 min intervals. In two models of inflammatory pain, capsaicin (0.3
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-carrageenan (2%) was injected into the hindpaw. Paw-
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search (CIHR), and Amgen Inc. G.M.P. is a CIHR postdoctoral fellow.loaded caliper (Mitutoyo). In a model of neuropathic pain (Mosconi
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